gmi-1359
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02931214)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
- Selectin EINHIBITOR
SELE inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gmi-1359
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04197999 | Phase 1 | Nov 21, 2019 | Duke University, GlycoMimetics, Inc. |
| NCT02931214 | Phase 1 | Aug 1, 2016 | Celerion, GlycoMimetics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlycoMimetics, Inc. | For profit | 2 | 2 | 1 | 2016 |
| Celerion | For profit | 1 | 0 | 1 | 2016 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1